These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 104814)

  • 41. C3 nephritic factor can be associated with membranous glomerulonephritis.
    Niel O; Dallocchio A; Thouret MC; Guigonis V; Cassuto É; Frémeaux-Bacchi V; Bérard É
    Pediatr Nephrol; 2015 Feb; 30(2):353-5. PubMed ID: 25395361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of complement by autoimmune antibodies isolated from sera of patients with membranoproliferative glomerulonephritis and systemic lupus erythematosus.
    Daha MR; Van Es LA
    Neth J Med; 1982; 25(7):202-7. PubMed ID: 6924073
    [No Abstract]   [Full Text] [Related]  

  • 43. Partial lipodystrophy and glomerulonephritis without complement activation.
    Mery JP; Kourilsky O; Morel-Maroger L; Adam C
    N Engl J Med; 1978 May; 298(18):1034. PubMed ID: 643001
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immunogloblin nature of nephritic factor (NeF).
    Scott DM; Amos N; Sissons JG; Lachmann PJ; Peters DK
    Clin Exp Immunol; 1978 Apr; 32(1):12-24. PubMed ID: 97036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Complement activating factors in hypocomplementemic membranoproliferative glomerulonephritis (MPGN) patients' sera--comparison with C3NeF positive and negative cases].
    Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
    Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):493-8. PubMed ID: 3656707
    [No Abstract]   [Full Text] [Related]  

  • 49. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).
    Ohi H; Watanabe S; Fujita T; Yasugi T
    Clin Exp Immunol; 1992 Sep; 89(3):479-84. PubMed ID: 1516262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
    Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
    J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A new C3NeF assay with zymosan-treated guinea-pig serum].
    Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
    Nihon Jinzo Gakkai Shi; 1986 Oct; 28(10):1423-7. PubMed ID: 3820819
    [No Abstract]   [Full Text] [Related]  

  • 52. Meningococcal meningitis associated with persistent hypocomplementaemia due to circulating C3 nephritic factor.
    Thompson RA; Yap PL; Brettle RB; Dunmow RE; Chapel H
    Clin Exp Immunol; 1983 Apr; 52(1):153-6. PubMed ID: 6861372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
    Daha MR; Fearon DT; Austen KF
    Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis.
    Bennett WM; Bardana EJ; Wuepper K; Houghton D; Border WA; Götze O; Schreiber R
    Am J Med; 1977 May; 62(5):757-60. PubMed ID: 860726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG?
    Davis AE; Arnaout MA; Alper CA; Rosen FS
    N Engl J Med; 1977 Jul; 297(3):144-5. PubMed ID: 865586
    [No Abstract]   [Full Text] [Related]  

  • 56. Serum bactericidal activity against Neisseria meningitidis in patients with C3 nephritic factors is dependent on IgG allotypes.
    Skattum L; Gullstrand B; Holmström E; Oxelius VA; Truedsson L
    Clin Immunol; 2008 Oct; 129(1):123-31. PubMed ID: 18667363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneity of nephritic factor and its identification as an immunoglobulin.
    Davis AE; Ziegler JB; Gelfand EW; Rosen FS; Alper CA
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):3980-3. PubMed ID: 269447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. C3 nephritic factor and SLE: report of four cases and review of the literature.
    Walport MJ; Davies KA; Botto M; Naughton MA; Isenberg DA; Biasi D; Powell RJ; Cheung NT; Struthers GR
    QJM; 1994 Oct; 87(10):609-15. PubMed ID: 7987656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective C3 deficiency due to C3 nephritic factor in an apparently healthy girl.
    Tedesco F; Tovo PA; Tamaro G; Basaglia M; Perticarari S; Villa MA
    Ric Clin Lab; 1985; 15(4):323-9. PubMed ID: 3834579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
    De Vecchi A; Montagnino G; Scalia P; Tarantino A
    Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.